Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 5;65(6):2500064.
doi: 10.1183/13993003.00064-2025. Print 2025 Jun.

Withdrawal of prostacyclin pathway therapies after initiation of sotatercept treatment in patients with pulmonary arterial hypertension

Karen M Olsson  1   2   3 , Jan Fuge  1   2   3 , Da-Hee Park  1   2 , Jan C Kamp  1   2 , Marius M Hoeper  4   2
Affiliations

Withdrawal of prostacyclin pathway therapies after initiation of sotatercept treatment in patients with pulmonary arterial hypertension

Karen M Olsson et al. Eur Respir J. .

Abstract

In a small series of PAH patients treated with sotatercept, withdrawal of selexipag was found to be safe, while discontinuation of parenteral treprostinil was feasible only in a subset of patients https://bit.ly/41UKcUi

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: K.M. Olsson has received fees for lectures or consultations from Acceleron, Actelion, AOP Health, Bayer, Ferrer, Janssen and MSD, all unrelated to the present work. J. Fuge has received fees for consultations from AstraZeneca unrelated to the submitted work. D-H. Park is supported by PRACTIS – Clinician Scientist Program at Hannover Medical School, funded by the German Research Foundation (DFG, ME 3696/3–1). J.C. Kamp is supported by PRACTIS – Clinician Scientist Program at Hannover Medical School, funded by the German Research Foundation (DFG, ME 3696/3-1). M.M. Hoeper has received fees for lectures or consultations from Acceleron, Actelion, AOP Health, Bayer, Ferrer, GossamerBio, Janssen, Keros and MSD, all unrelated to the present work.

References

    1. Humbert M, Kovacs G, Hoeper MM, et al. . 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2022; 61: 2200879. doi:10.1183/13993003.00879-2022 - DOI - PubMed
    1. Mai V, Gosselin C, Tremblay E, et al. . Patients’ perceptions on clinical trials outcomes in pulmonary arterial hypertension therapy. Thorax 2023; 78: 721–725. doi:10.1136/thorax-2022-219490 - DOI - PubMed
    1. Humbert M, McLaughlin V, Gibbs JSR, et al. . Sotatercept for the treatment of pulmonary arterial hypertension. N Engl J Med 2021; 384: 1204–1215. doi:10.1056/NEJMoa2024277 - DOI - PubMed
    1. Hoeper MM, Badesch DB, Ghofrani HA, et al. . Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension. N Engl J Med 2023; 388: 1478–1490. doi:10.1056/NEJMoa2213558 - DOI - PubMed
    1. Souza R, Badesch DB, Ghofrani HA, et al. . Effects of sotatercept on haemodynamics and right heart function: analysis of the STELLAR trial. Eur Respir J 2023; 62: 2301107. doi:10.1183/13993003.01107-2023 - DOI - PMC - PubMed

LinkOut - more resources